| Date | Time | Source | Headline | Symbol | Company |
| 12/12/2023 | 5:50AM | IH Market News | Hasbro Job Cuts, Oracle’s Stock Decline, Google’s Epic Antitrust Loss, and More | NYSE:ABBV | AbbVie Inc |
| 12/09/2023 | 12:00PM | PR Newswire (US) | New Data for Bispecific Antibody Epcoritamab (DuoBody® CD3xCD20) Shows Strong, Durable Treatment Response for Patients with Difficult-To-Treat Relapsed/Refractory (R/R) Follicular Lymphoma (FL) | NYSE:ABBV | AbbVie Inc |
| 12/08/2023 | 10:28AM | Dow Jones News | AbbVie Currently Up Eight Consecutive Days, on Track for Longest Winning Streak Since December 2021 -- Data Talk | NYSE:ABBV | AbbVie Inc |
| 12/08/2023 | 6:23AM | IH Market News | Apple Boosts Vietnam Production, Broadcom Revenue Miss, Stellantis Job Cuts – Latest Updates | NYSE:ABBV | AbbVie Inc |
| 12/07/2023 | 11:48AM | Dow Jones News | AbbVie Currently Up Seven Consecutive Days, on Track for Longest Winning Streak Since December 2021 -- Data Talk | NYSE:ABBV | AbbVie Inc |
| 12/07/2023 | 10:27AM | Dow Jones News | Trending: AbbVie to Buy Cerevel for $45 a Share | NYSE:ABBV | AbbVie Inc |
| 12/07/2023 | 6:23AM | IH Market News | Alphabet Unveils Advanced AI Model, AMD Expects $45 Billion AI Market, Chevron’s $19.5B Investment Plans, BMY Increases Dividend, and More | NYSE:ABBV | AbbVie Inc |
| 12/06/2023 | 5:28PM | Edgar (US Regulatory) | Form 8-K - Current report | NYSE:ABBV | AbbVie Inc |
| 12/06/2023 | 5:10PM | Dow Jones News | AbbVie to Buy Cerevel Therapeutics for $8.7 Billion -- Update | NYSE:ABBV | AbbVie Inc |
| 12/06/2023 | 5:05PM | Dow Jones News | AbbVie to Buy Cerevel Therapeutics for $8.7 Billion | NYSE:ABBV | AbbVie Inc |
| 12/06/2023 | 4:59PM | Dow Jones News | AbbVie Close to $8 Billion Deal for Cerevel Therapeutics, Sources Say, Reuters Reports | NYSE:ABBV | AbbVie Inc |
| 12/06/2023 | 4:30PM | PR Newswire (US) | AbbVie to Acquire Cerevel Therapeutics in Transformative Transaction to Strengthen Neuroscience Pipeline | NYSE:ABBV | AbbVie Inc |
| 12/05/2023 | 8:45AM | PR Newswire (US) | AbbVie and BigHat Biosciences Announce Research Collaboration to Leverage Artificial Intelligence and Machine Learning to Discover Next-Generation Therapeutic Antibodies | NYSE:ABBV | AbbVie Inc |
| 11/30/2023 | 8:47AM | Edgar (US Regulatory) | Form 8-K - Current report | NYSE:ABBV | AbbVie Inc |
| 11/30/2023 | 8:42AM | Dow Jones News | ImmunoGen Shares Soar Premarket on Takeover by AbbVie | NYSE:ABBV | AbbVie Inc |
| 11/30/2023 | 8:13AM | Dow Jones News | AbbVie to Buy ImmunoGen for More Than $10 Billion | NYSE:ABBV | AbbVie Inc |
| 11/30/2023 | 7:30AM | PR Newswire (US) | AbbVie to Acquire ImmunoGen, including its Flagship Cancer Therapy ELAHERE® (mirvetuximab soravtansine-gynx), Expanding Solid Tumor Portfolio | NYSE:ABBV | AbbVie Inc |
| 11/29/2023 | 10:12AM | Dow Jones News | AbbVie's Experimental Therapy Shows Reduction in Type of Lung Cancer in Phase 2 Study | NYSE:ABBV | AbbVie Inc |
| 11/29/2023 | 8:45AM | PR Newswire (US) | AbbVie Announces Positive Topline Results from Phase 2 LUMINOSITY Trial Evaluating Telisotuzumab-Vedotin (Teliso-V) for Patients with Previously Treated Non-Small Cell Lung Cancer (NSCLC) | NYSE:ABBV | AbbVie Inc |
| 11/27/2023 | 7:00AM | PR Newswire (US) | AbbVie Announces U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) Updates for Epcoritamab (EPKINLY®/TEPKINLY®) for the Treatment of Relapsed/Refractory Follicular Lymphoma | NYSE:ABBV | AbbVie Inc |
| 11/20/2023 | 8:45AM | PR Newswire (US) | Fifth Annual BOTOX® Cosmetic (onabotulinumtoxinA) Day Makes History as the Biggest Day Ever | NYSE:ABBV | AbbVie Inc |
| 11/16/2023 | 4:21PM | AllPennyStocks.com | Take Part in the Next Generation of Spinal Cord Injury Treatments with These Companies | NYSE:ABBV | AbbVie Inc |
| 11/16/2023 | 4:21PM | AllPennyStocks.com | Take Part in the Next Generation of Spinal Cord Injury Treatments with These Companies | NYSE:ABBV | AbbVie Inc |
| 11/16/2023 | 7:00AM | PR Newswire (US) | Results Published in The Lancet Show UBRELVY® (ubrogepant) Reduces the Headache Phase of a Migraine Attack When Dosed During the Prodrome of Migraine | NYSE:ABBV | AbbVie Inc |
| 11/13/2023 | 4:05PM | GlobeNewswire Inc. | NEXGEL Reports Record Third Quarter 2023 Revenue of $1.2 Million, an Increase of 115% Year-Over-Year | NYSE:ABBV | AbbVie Inc |
| 11/08/2023 | 8:45AM | PR Newswire (US) | Natrelle® Unveils New "For Every BODY" Campaign | NYSE:ABBV | AbbVie Inc |
| 11/06/2023 | 1:01PM | Edgar (US Regulatory) | Form 10-Q - Quarterly report [Sections 13 or 15(d)] | NYSE:ABBV | AbbVie Inc |
| 11/02/2023 | 8:31AM | PR Newswire (US) | Roundhill Investments Launches Dividend Monarchs ETF (NYSE Arca: KNGS) | NYSE:ABBV | AbbVie Inc |
| 11/01/2023 | 2:27PM | Dow Jones News | Aldeyra Shares Continue to Rally After AbbVie Agrees to Licensing Option | NYSE:ABBV | AbbVie Inc |
| 11/01/2023 | 8:48AM | Dow Jones News | Aldeyra Shares Rally After AbbVie Licensing Deal on Eye Drug | NYSE:ABBV | AbbVie Inc |